Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Dec

Today In Oncology

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers

FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL

Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening

AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease

Survey Finds Global Embrace of Integrative Cancer Care